Healthy, Psoriasis Vulgaris
Conditions
Keywords
Psoriasis, Sodium, Skin
Brief summary
Sodium can be buffered in the skin, which mechanism is altered during aging and in certain diseases such as hypertension. High salt environment can promote autoimmunity by expanding pathogenic IL-17 producing T helper (Th17) cells. Psoriasis is a relapsing and remitting inflammatory autoimmune disease affecting the skin and joints and involves proinflammatory Th17 cells. Here we tested the hypothesis if psoriatic skin has a higher sodium content in humans.
Detailed description
The cytokine interleukin-17A (IL-17A) is a crucial player in the pathogenesis of the autoimmune disease of psoriasis. This neutrophil recruiting cytokine is produced by IL-17A producing CD4+ T cells (Th17) and gamma/delta T cells of the skin and evokes an inflammation circuit finally leading to the classical clinical picture of psoriasis with hyper- and parakeratosis, erythema, scaling and neutrophil abscess formation. Besides genetic factors, lifestyle factors are relevant and decide if an autoimmune disease becomes manifest. It was shown previously that increased salt (sodium chloride, NaCl) concentrations boost the induction of murine and human Th17 cells. However, more - and also clinical - studies are needed to understand the correlation between salt content and IL-17A in autoimmune diseases. This study investigates the hypothesis if skin sodium content in human psoriasis is increased in order to get further insight into the IL-17A-salt-interplay.
Interventions
DIAGNOSTIC_TEST23Na Magnetic resonance imaging
Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.
Sponsors
German Heart Center
Charite University, Berlin, Germany
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* Age: 18-80 * Body mass index (BMI) 18.5- 40 kg/m2 * Glomerular filtration rate \>60 ml/min/1.73m2
Exclusion criteria
* Diagnosed or treated hypertension and/or blood pressure above 140/90 at screening * Palpable peripheral oedema during phyisical examination at screening * Any type of diabetes mellitus and/or HgbA1c\>6.5% at screening * Subjects with a thyroid-stimulating hormone \>4.2 mU/L at screening * Psoriasis patients treated with systemic corticosteroids, chemotherapy agent (methothrexate) or with any kind of biologics/biosimilars * Subjects with acute disease * Pregnant or lactating women * Metal or medical device implant in the body * Tattoo on the lower extremities * Subjects with a history of drug or alcohol abuse * Subjects who are legal incapacitated or their circumstances do not enable the patient to fully understand the nature, significance and scope of this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Non-invasive sodium measurement in the skin | 4 years | Sodium measured in the skin by 23Na-MRI is higher in psoriasis patients vs. matched healthy individuals. |
Countries
Germany
Outcome results
None listed